A retrospective study of nivolumab and pembrolizumab in patients with metastatic melanoma
Latest Information Update: 01 Dec 2016
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2016 New trial record
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.